secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2023-07-24T23:59:59+00:00
Accession:  0001104659-23-083457
Event type: litigation
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics wins Federal Circuit appeal in Liquidia patent litigation; Yutrepia approval delayed
--------------------------------------------------------------------------------

- Federal Circuit affirmed Liquidia's Yutrepia infringes United Therapeutics' '793 patent; FDA approval blocked until patent expires May 14, 2027.
- Court confirmed Liquidia would induce infringement by marketing Yutrepia; all '793 claims held valid over invalidity challenges.
- Federal Circuit also affirmed certain claims of U.S. Patent No. 9,593,066 are either invalid or not infringed by Liquidia.
- Both parties may request rehearing; PTAB IPR decision finding '793 unpatentable is on appeal by United Therapeutics.
- District court order barring FDA final approval remains unless infringed claims are found invalid after exhaustion of appeals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000110465923083457/0001104659-23-083457-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000110465923083457/tm2321916d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-083457

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer